Vefy Report
The GLP-1 Revolution: what the evidence actually shows, and what the internet keeps flattening
Evidence maturity
The category is real, the spillover is real, and the flattening is the problem.
Report note: This page is not medical advice and not a weight-loss hype page. It is a narrative investigation built to separate approved GLP-1 evidence, compounded-product risk, and viral claim inflation instead of collapsing them into one emotional conclusion.
Confidence
77 · Evidence maturity
The category is real, the spillover is real, and the flattening is the problem.
The answer first, then the evidence path behind it.
The strongest Vefy read is not miracle drug versus scam. It is that FDA-approved GLP-1 products, compounded or unapproved versions, and viral anecdote culture are three different evidence lanes. Most public confusion comes from treating them as one argument.
People say GLP-1 and then mix together Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide, dosing mistakes, muscle-loss anxiety, and broader body-image discourse as if they are one claim. They are not.
Timeline
If timing changed the read, this is the sequence that mattered.
Reasoning and proof